Beyond Second-Line Chemotherapy for Breast Cancer - priME Oncology

Beyond Second-Line Chemotherapy for Breast Cancer

Not a member of My prIME? Join now for instant access.

Beyond Second-Line Chemotherapy for Breast Cancer

View Activity

Activity Overview

This CME-certified virtual monograph based on a roundtable workshop held in New York, New York, on Saturday, January 30, 2016, with video commentary from breast cancer experts and clinical opinion poll questions, focuses on the treatment of metastatic breast cancer, specifically beyond second-line treatment.


Table of Contents

  • Advanced Breast Cancer (ABC) in 2016—Current Status and Challenges
  • Treatment Options in Anthracycline-Pretreated and Taxane-Pretreated ABC
  • Ixabepilone in ABC: Who? When? And How?
  • Conclusions
  • References
  • Adam Brufsky, MD, PhD, FACPUniversity of Pittsburgh
    Pittsburgh, Pennsylvania, United States
  • Harold J. Burstein, MD, PhDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
    University of Sheffield
    Weston Park Hospital
    Sheffield, United Kingdom
  • Monica Fornier, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Joyce O’Shaughnessy, MDBaylor University Medical Center
    Texas Oncology
    US Oncology
    Dallas, Texas, United States
  • Hope S. Rugo, MD, FASCOUniversity of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California, United States
  • Denise Yardley, MDSarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee, United States

Target Audience

This educational activity is specifically designed for medical oncologists, fellows, nurses, physician assistants, nurse practitioners, and other healthcare providers who treat/manage patients with metastatic breast cancer.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Incorporate therapies for advanced/metastatic breast cancer into individualized treatment plans for patients based upon an evaluation of efficacy and safety data, as well as patient and tumor characteristics
  • Assess clinical trial data for the use of epothilones in (neo)adjuvant therapy and combinations with targeted treatment
  • Identify common or significant adverse events associated with treatment of advanced/metastatic breast cancer beyond the second-line setting, and the effective strategies for their prevention and/or management
View Activity


This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.


prIME Oncology designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This continuing nursing education activity was approved by the Oncology Nursing Society, an accredited approver by the American Nurses Credentialing Center’s COA.

This activity has been approved for 1.3 contact hours.


This educational activity is supported by a grant from R-Pharm US.

Activity Date

March 31, 2016

October 31, 2017